Effect of Palmitoylethanolamide (PEA) compared to a placebo on symptoms for upperrespiratory tract infection (URTI) in an Adult Population – A double blind, randomised controlledtrial.

RDC Global Pty Ltd0 个研究点目标入组 428 人开始时间: 2020年8月27日最近更新: 2022年3月7日

试验速览

暂无简介。

•Male and females aged 18-65 years old
•- Able to provide informed consent
•- Agree not to take other supplements (e.g. Echinacea, Vitamin C, zinc) or medications (e.g. Tamiflu, Relenza) aimed at preventing URTIs for the duration of the trial (3 months).

•- Unstable or serious illness (e.g. kidney, liver, GIT, heart conditions, diabetes, thyroid gland function, Malignancy, lung conditions or chronic asthma)*
•- Acute sickness experienced in the past 2 months
•- Serious mood disorders or neurological disorders such as MS
•- Active smokers and/or nicotine or drug abuse
•- Chronic alcohol use (>14 alcoholic drinks week)
•- Allergic to any of the ingredients in active or placebo formula
•- Pregnant or lactating woman
•- People medically prescribed medications that would affect the immune and/or the inflammatory response.
•- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
•- Participants who have participated in any other related clinical study during the past 1 month
•- People with cognitive damage
•- People who have or have had treatment for cancer, HIV or chronic use of any dose of steroids (cream, tablet or inhalant) in the past year
•*An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

发起方